Heron Therapeutics Faces Critical Earnings Test

The upcoming quarterly report from Heron Therapeutics represents a pivotal moment for the biotechnology firm’s stock performance. Scheduled for release before markets open on Tuesday, the Q3 2025 financial results arrive amid conflicting signals: substantial insider purchasing contrasts sharply with concerning technical indicators, creating uncertainty about the stock’s future trajectory.

While technical charts paint a bleak picture, corporate insiders have demonstrated significant conviction through recent purchases. In August, Director Adam Morgan joined major shareholder Rubric Capital Management in acquiring substantial positions. Rubric’s transaction involved purchasing more than 2.3 million shares at approximately $1.50 per share, representing an investment exceeding $3.5 million. This buying spree increased Rubric’s total holdings to over 29 million Read more...